Akt inhibitors (afuresertib, capivasertib, ipatasertib, TAS-117, triciribin, uprosertib, and in lung cancer: MK-2206) are also being studied in phase II and III trials for the treatment of advanced cancers (NCT01147211). Here, AKT1 is linked to lung cancer.